000155568 001__ 155568
000155568 005__ 20230915092329.0
000155568 0247_ $$2doi$$a10.1038/s41577-021-00543-w
000155568 0247_ $$2pmid$$apmid:33976421
000155568 0247_ $$2pmc$$apmc:PMC8111372
000155568 0247_ $$2ISSN$$a1474-1733
000155568 0247_ $$2ISSN$$a1474-1741
000155568 0247_ $$2altmetric$$aaltmetric:105759189
000155568 037__ $$aDZNE-2021-00746
000155568 041__ $$aEnglish
000155568 082__ $$a570
000155568 1001_ $$0P:(DE-2719)2810931$$aPrüß, Harald$$b0$$eFirst author$$udzne
000155568 245__ $$aAutoantibodies in neurological disease.
000155568 260__ $$aLondon$$bNature Publ. Group$$c2021
000155568 3367_ $$2DRIVER$$aarticle
000155568 3367_ $$2DataCite$$aOutput Types/Journal article
000155568 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1638521305_6778
000155568 3367_ $$2BibTeX$$aARTICLE
000155568 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000155568 3367_ $$00$$2EndNote$$aJournal Article
000155568 520__ $$aThe realization that autoantibodies can contribute to dysfunction of the brain has brought about a paradigm shift in neurological diseases over the past decade, offering up important novel diagnostic and therapeutic opportunities. Detection of specific autoantibodies to neuronal or glial targets has resulted in a better understanding of central nervous system autoimmunity and in the reclassification of some diseases previously thought to result from infectious, 'idiopathic' or psychogenic causes. The most prominent examples, such as aquaporin 4 autoantibodies in neuromyelitis optica or NMDAR autoantibodies in encephalitis, have stimulated an entire field of clinical and experimental studies on disease mechanisms and immunological abnormalities. Also, these findings inspired the search for additional autoantibodies, which has been very successful to date and has not yet reached its peak. This Review summarizes this rapid development at a point in time where preclinical studies have started delivering fundamental new data for mechanistic understanding, where new technologies are being introduced into this field, and - most importantly - where the first specifically tailored immunotherapeutic approaches are emerging.
000155568 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000155568 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000155568 650_2 $$2MeSH$$aAnimals
000155568 650_2 $$2MeSH$$aAquaporin 4: immunology
000155568 650_2 $$2MeSH$$aAutoantibodies: immunology
000155568 650_2 $$2MeSH$$aAutoimmunity
000155568 650_2 $$2MeSH$$aBrain: immunology
000155568 650_2 $$2MeSH$$aBrain: physiopathology
000155568 650_2 $$2MeSH$$aEncephalitis: immunology
000155568 650_2 $$2MeSH$$aEncephalitis: physiopathology
000155568 650_2 $$2MeSH$$aEncephalitis: therapy
000155568 650_2 $$2MeSH$$aHumans
000155568 650_2 $$2MeSH$$aNeuromyelitis Optica: immunology
000155568 650_2 $$2MeSH$$aNeuromyelitis Optica: physiopathology
000155568 650_2 $$2MeSH$$aNeuromyelitis Optica: therapy
000155568 650_2 $$2MeSH$$aReceptors, N-Methyl-D-Aspartate: immunology
000155568 773__ $$0PERI:(DE-600)2060551-1$$a10.1038/s41577-021-00543-w$$n12$$p798-813$$tNature reviews / Immunology$$v21$$x1474-1741$$y2021
000155568 8564_ $$uhttps://www.nature.com/articles/s41577-021-00543-w
000155568 909CO $$ooai:pub.dzne.de:155568$$pVDB
000155568 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810931$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000155568 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000155568 9130_ $$0G:(DE-HGF)POF3-342$$1G:(DE-HGF)POF3-340$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lErkrankungen des Nervensystems$$vDisease Mechanisms and Model Systems$$x0
000155568 9141_ $$y2021
000155568 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-26
000155568 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-26
000155568 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2022-11-23$$wger
000155568 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-23
000155568 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-23
000155568 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-23
000155568 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-23
000155568 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-23
000155568 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-23
000155568 915__ $$0StatID:(DE-HGF)1120$$2StatID$$aDBCoverage$$bBIOSIS Reviews Reports And Meetings$$d2022-11-23
000155568 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNAT REV IMMUNOL : 2021$$d2022-11-23
000155568 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-23
000155568 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-23
000155568 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-23
000155568 915__ $$0StatID:(DE-HGF)9990$$2StatID$$aIF >= 90$$bNAT REV IMMUNOL : 2021$$d2022-11-23
000155568 9201_ $$0I:(DE-2719)1810003$$kAG Prüß$$lAutoimmune Enzephalopathies$$x0
000155568 980__ $$ajournal
000155568 980__ $$aVDB
000155568 980__ $$aI:(DE-2719)1810003
000155568 980__ $$aUNRESTRICTED